Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults: A Randomized Control Trial
Mohsen Saidinejad
Summary
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Eligibility
- Age range
- 5–20 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Between the ages 5-20 years * Diagnosed sickle cell disease. Homozygous (HbSS) or heterozygous (HbSC, HbSBetaThal Plus or Zero) will be included. * Presenting with VOE pain, requiring IV pain medication. * First dose of analgesic medication is given before patient approached for participation in the study. * Primary language is English or Spanish * Adult individual or parent/legal guardian is able and willing to provide informed consent. For individuals 7 to 17 years of age, assent must also be provided when cognitively possible. Exclusion Criteria: * Sickle cell trait…
Interventions
- DrugSub-dissociative Ketamine Infusion
0.25 mg/kg of IV ketamine within a 20-minute infusion of 100 milliliters of normal saline (NS)
- DrugNormal Saline Placebo Infusion
20-minute infusion of 100 milliliters of normal saline
Location
- Harbor UCLA Medical CenterTorrance, California